Trial Profile
A phase II trial of pemetrexed in combination with gemcitabine as first line treatment in extensive-stage small cell lung carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2017
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 26 Oct 2007 Status change from recruiting to discontinued; due to a failure to accrue.
- 30 Oct 2005 New trial record.